Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adding 20% Tax Would Curb Abuse Of OTC Drugs For Trimming Pounds, Research Suggests

Executive Summary

National Eating Disorders Association-funded study projects tax would reduce purchases 10.3% for households with female children and 5.2% for all families. “Abuse of widely available, over-the-counter drugs and supplements such as diet pills, laxatives and diuretics by adolescents for weight control is well documented, yet manufacturers and retailers can sell them to minors without restriction,” says study author Bryn Austin of Harvard Medical School.

You may also be interested in...

Massachusetts Bid Stalls To Age-Restrict Sales Of Bodybuilding, Weight Loss Supplements

"We spent a lot of time in Massachusetts trying to point out the flaws in the legislation," says CRN government relations chief Mike Greene. CRN and other stakeholders could focus on the Massachusetts bill because no other similar proposals surfaced in other state legislatures this year.

Limiting Sport Supplement Sales To Minors Recommended By More Researchers

More than two-thirds of health food stores’ staff recommended creatine to researchers posing as teen athletes, results that researchers say should prompt pediatricians and retailers to educate young people on the risk of creatine and push states to ban sales of the substance to minors.

Alli Labels In U.S. Add Seizure Advisory Similar To E.U. Change

GSK also recently posted to the alli brand website statements on why language was added to the Drug Facts panel for the orlistat 60 mg product. FDA contacted Glaxo in November 2013 requesting a supplement NDA for the label change, FDA’s Division of Nonprescription Clinical Evaluation said.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts